Provista Diagnostics is a privately held molecular diagnostics company headquartered in New York that develops and commercializes proteomic-based diagnostic, prognostic and monitoring blood tests for cancers affecting women, including breast and gynecologic cancers. Its proprietary, blood-based tests aim to address unmet needs in early detection and monitoring. The company operates a state-of-the-art, high-complexity clinical laboratory accredited by the College of American Pathologists (CAP) and certified under CLIA by CMS. On March 21, 2016, Provista closed an additional $5.25 million in preferred financing comprised of capital from existing investors exercising warrants from a previous financing. Proceeds will fund continued commercial development, prospective clinical trials, key management hires, and general corporate purposes. Provista has raised a total of $37.9 million since 2011. Provista Diagnostics is a privately held molecular diagnostics company headquartered in New York focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic, and monitoring tests designed to address unmet needs in woman's cancer, such as breast and gynecologic cancers. The company operates a state-of-the-art, high-complexity clinical laboratory accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be CLIA-compliant. On Aug. 4, 2015, Provista announced the closing of $6.0 million in Series A-2 Preferred financing, with all proceeds coming from existing investors exercising warrants from a prior round. Provista has raised a total of $32.7 million since 2011. The proceeds from the latest round are intended for continued commercial development, prospective clinical trials, key management hires, and general corporate purposes. CEO David E. Reese, Ph.D., expressed gratitude to investors for their confidence in the company's product and business plan. Provista Diagnostics develops and commercializes proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast and ovarian. The company offers diagnostic testing and clinical laboratory services to pharmaceutical and biotechnology industries through Provista Companion Diagnostics, a CLIA-accredited and GLP-capable laboratory licensed in 49 states to perform human clinical testing. Provista is led by President and CEO David Reese, Ph.D., and is based in Scottsdale, Arizona and New York. The company closed a $6.0m Series B financing and has now raised $19.5m in total. It plans to use the funds to expand commercial market development for its dtectDx-Breast assay and to pursue additional clinical trials. Provista is also working toward 510(k) regulatory clearances for the dtectDx-Breast assay. Provista Diagnostics develops and commercializes blood-based diagnostic tests for early oncology-related disease state recognition and provides clinical laboratory services to the pharmaceutical and biotechnology industries. Its lead test, dtectDx-Breast (formerly BT Test), detects biomarkers from a blood sample and is intended to be used alongside mammography to support early breast cancer detection. The company is led by President and CEO Dr. David Reese. Provista intends to use capital to expand laboratory capabilities, complete clinical trials, and pursue regulatory submission for dtectDx-Breast. Additional uses of proceeds include general corporate purposes and development of pipeline products. The company raised $2.5m in a Series A financing from existing investors (not disclosed). Provista Diagnostics is a cancer detection and diagnostics company focused on women’s cancers and develops blood-based tests such as the BT Test® for use alongside mammography. The company has partnerships that provide access to innovative molecular oncology biomarkers. Near-term development priorities include completing a confirmatory clinical trial and submitting a 510(k) to the FDA for the BT Test®. Provista intends to use the majority of new financing to fund that clinical and regulatory work, with a portion allocated to repay outstanding short-term debt. The company states its focus area also includes ovarian cancer and early detection testing for lung cancer. Provista is based in Phoenix, Arizona and is organized as a Delaware company.

Total raised

$25M

Funding rounds

5

Latest round

Preferred

Latest activity

Mar 2016